Evidence map›Paper›PMID 39906042›Full record

ArticleFrontiers in endocrinology2024

Development and validation of machine learning models for MASLD: based on multiple potential screening indicators.

Hao Chen, Jingjing Zhang, Xueqin Chen, Ling Luo, Wenjiao Dong, Yongjie Wang, Jiyu Zhou, Canjin Chen, Wenhao Wang, Wenbin Zhang and 4 more

Abstract readValidation Study
In one paragraph

Article in Frontiers in endocrinology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Hao Chen *Department of Epidemiology and Medical Statistics School of Public Health, Guangdong Medical University, Dongguan, Guangdong, China.
Jingjing Zhang *Department of Epidemiology and Medical Statistics School of Public Health, Guangdong Medical University, Dongguan, Guangdong, China.
Xueqin Chen *Department of Epidemiology and Medical Statistics School of Public Health, Guangdong Medical University, Dongguan, Guangdong, China.
Ling LuoDepartment of Epidemiology and Medical Statistics School of Public Health, Guangdong Medical University, Dongguan, Guangdong, China.
Wenjiao DongDepartment of Epidemiology and Medical Statistics School of Public Health, Guangdong Medical University, Dongguan, Guangdong, China.
Yongjie WangDepartment of Epidemiology and Medical Statistics School of Public Health, Guangdong Medical University, Dongguan, Guangdong, China.
Jiyu ZhouDepartment of Epidemiology and Medical Statistics School of Public Health, Guangdong Medical University, Dongguan, Guangdong, China.
Canjin ChenDepartment of Epidemiology and Medical Statistics School of Public Health, Guangdong Medical University, Dongguan, Guangdong, China.
Wenhao WangDepartment of Epidemiology and Medical Statistics School of Public Health, Guangdong Medical University, Dongguan, Guangdong, China.
Wenbin ZhangDepartment of Epidemiology and Medical Statistics School of Public Health, Guangdong Medical University, Dongguan, Guangdong, China.
Zhiyi ZhangDepartment of Epidemiology and Medical Statistics School of Public Health, Guangdong Medical University, Dongguan, Guangdong, China.
Yongguang CaiDepartment of Medical Oncology, Central Hospital of Guangdong Nongken, Zhanjiang, Guangdong, China.
Danli KongDepartment of Epidemiology and Medical Statistics School of Public Health, Guangdong Medical University, Dongguan, Guangdong, China.
Yuanlin DingDepartment of Epidemiology and Medical Statistics School of Public Health, Guangdong Medical University, Dongguan, Guangdong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Multifaceted factors play a crucial role in the prevention and treatment of metabolic dysfunction-associated steatotic liver disease (MASLD). This study aimed to utilize multifaceted indicators to construct MASLD risk prediction machine learning models and explore the core factors within these models. Methods: MASLD risk prediction models were constructed based on seven machine learning algorithms using all variables, insulin-related variables, demographic characteristics variables, and other indicators, respectively. Subsequently, the partial dependence plot(PDP) method and SHapley Additive exPlanations (SHAP) were utilized to explain the roles of important variables in the model to filter out the optimal indicators for constructing the MASLD risk model. Results: Ranking the feature importance of the Random Forest (RF) model and eXtreme Gradient Boosting (XGBoost) model constructed using all variables found that both homeostasis model assessment of insulin resistance (HOMA-IR) and triglyceride glucose-waist circumference (TyG-WC) were the first and second most important variables. The MASLD risk prediction model constructed using the variables with top 10 importance was superior to the previous model. The PDP and SHAP methods were further utilized to screen the best indicators (including HOMA-IR, TyG-WC, age, aspartate aminotransferase (AST), and ethnicity) for constructing the model, and the mean area under the curve value of the models was 0.960. Conclusions: HOMA-IR and TyG-WC are core factors in predicting MASLD risk. Ultimately, our study constructed the optimal MASLD risk prediction model using HOMA-IR, TyG-WC, age, AST, and ethnicity.

Indexed as

Fatty LiverMachine LearningAdultFemaleHumansInsulin ResistanceMaleMiddle AgedRisk AssessmentRisk Factorsinsulin resistancemachine learningmetabolic dysfunction-associated steatotic liver diseaserisk prediction modeltriglyceride glucose

Identifiers

PMID39906042
PMCPMC11790477

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.